Dare Bioscience Stock Performance
| DARE Stock | USD 2.68 0.16 6.35% |
The firm shows a Beta (market volatility) of -0.23, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Dare Bioscience are expected to decrease at a much lower rate. During the bear market, Dare Bioscience is likely to outperform the market. At this point, Dare Bioscience has a negative expected return of -0.15%. Please make sure to confirm Dare Bioscience's kurtosis, and the relationship between the maximum drawdown and rate of daily change , to decide if Dare Bioscience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Dare Bioscience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.8 | Five Day Return (10.32) | Year To Date Return (21.74) | Ten Year Return (99.51) | All Time Return (99.69) |
Last Split Factor 1:12 | Dividend Date 2017-07-20 | Last Split Date 2024-07-01 |
1 | Dare Bioscience Expands Strategy to Enhance Value for Stakeholders DARE Stock News | 05/13/2025 |
2 | Q1 2025 Dare Bioscience Inc Earnings Call Transcript | 05/14/2025 |
3 | Dar Bioscience Share Price Crosses Below Two Hundred Day Moving Average Time to Sell | 05/16/2025 |
4 | Dar Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Dars DARE to PLAY Sildenafil Cream | 06/04/2025 |
5 | Is Boston Scientific Stock Outpacing Its Medical Peers This Year | 06/06/2025 |
6 | Dar Bioscience Announces Adjournment of Annual Meeting of Stock | 06/12/2025 |
7 | Dar Bioscience Gains Nasdaq Compliance Extension Approval - TipRanks | 06/25/2025 |
8 | Dar Bioscience Receives 6 Million Non-Dilutive Grant Installme | 07/11/2025 |
9 | Positive Interim Phase 3 Results Highlight Potential of Ovaprene | 07/14/2025 |
| Begin Period Cash Flow | 10.8 M | |
| Total Cashflows From Investing Activities | -573 K |
Dare Bioscience Relative Risk vs. Return Landscape
If you would invest 297.00 in Dare Bioscience on April 22, 2025 and sell it today you would lose (40.00) from holding Dare Bioscience or give up 13.47% of portfolio value over 90 days. Dare Bioscience is currently does not generate positive expected returns and assumes 4.1571% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Dare, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dare Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dare Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dare Bioscience, and traders can use it to determine the average amount a Dare Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0356
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DARE |
Estimated Market Risk
| 4.16 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Dare Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dare Bioscience by adding Dare Bioscience to a well-diversified portfolio.
Dare Bioscience Fundamentals Growth
Dare Stock prices reflect investors' perceptions of the future prospects and financial health of Dare Bioscience, and Dare Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dare Stock performance.
| Return On Equity | -9.95 | ||||
| Return On Asset | -0.87 | ||||
| Operating Margin | (180.17) % | ||||
| Current Valuation | 15.55 M | ||||
| Shares Outstanding | 8.85 M | ||||
| Price To Earning | (43.44) X | ||||
| Price To Book | 10.75 X | ||||
| Price To Sales | 860.82 X | ||||
| Revenue | 9.78 K | ||||
| Gross Profit | (13.22 M) | ||||
| EBITDA | (23.41 M) | ||||
| Net Income | (4.05 M) | ||||
| Cash And Equivalents | 40.39 M | ||||
| Cash Per Share | 0.48 X | ||||
| Total Debt | 1.3 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 2.17 X | ||||
| Book Value Per Share | (1.08) X | ||||
| Cash Flow From Operations | 5.39 M | ||||
| Earnings Per Share | (0.17) X | ||||
| Market Capitalization | 22.3 M | ||||
| Total Asset | 22.1 M | ||||
| Retained Earnings | (175.29 B) | ||||
| Working Capital | (3.16 M) | ||||
| Current Asset | 7.58 M | ||||
| Current Liabilities | 17.82 M | ||||
About Dare Bioscience Performance
By analyzing Dare Bioscience's fundamental ratios, stakeholders can gain valuable insights into Dare Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dare Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dare Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -39.3 M | -41.3 M | |
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (47.65) | (45.27) | |
| Return On Assets | (0.18) | (0.19) |
Things to note about Dare Bioscience performance evaluation
Checking the ongoing alerts about Dare Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dare Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dare Bioscience generated a negative expected return over the last 90 days | |
| Dare Bioscience has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 9.78 K. Net Loss for the year was (4.05 M) with loss before overhead, payroll, taxes, and interest of (13.22 M). | |
| Dare Bioscience has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Positive Interim Phase 3 Results Highlight Potential of Ovaprene |
- Analyzing Dare Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dare Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Dare Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dare Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dare Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dare Bioscience's stock. These opinions can provide insight into Dare Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Dare Stock analysis
When running Dare Bioscience's price analysis, check to measure Dare Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dare Bioscience is operating at the current time. Most of Dare Bioscience's value examination focuses on studying past and present price action to predict the probability of Dare Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dare Bioscience's price. Additionally, you may evaluate how the addition of Dare Bioscience to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |